Skip to main content

Table 2 Main clinical outcomes of the project at 4 weeks after treatment change

From: Safely reducing haemodialysis frequency during the COVID-19 pandemic

 

Twice weekly HD

Thrice weekly HD

P value

URR (%)a

72.6 [66.4–77.2]

69.7 [62.7–74.8]

0.009

Corrected Calciumb (mmol/L)

2.33 [2.20–2.42]

2.33 [2.22–2.43]

0.921

Phosphatec (mmol/L)

1.77 [1.44]

1.65 [1.33–2.09]

0.117

Potassiumd (mmol/L)

4.80 [4.30–5.40]

4.90 [4.40–5.40]

0.329

UF per session (L)

1.50 [1.00–2.03]

2.00 [1.40–2.63]

< 0.001

COVID-19 positive (%)

9 (5.4)

20 (8.5)

0.245

Hospitalisations (%)

13 (7.8)

17 (7.2)

0.813

Deaths (%)

6 (3.6)

6 (2.5)

0.535

  1. Results are expressed as median [IQR; interquartile range] or n (%). p-value calculated using Mann-Whitney U Test. Categorical variables were analysed by Chi-square test. Hospitalisation data includes patients who were hospitalised for COVID-19 and prior to death. amissing for 56 patients in twice weekly group and 126 patients in thrice weekly group. bmissing for 9 patients in twice weekly group and 46 patients in thrice weekly group. cmissing for 9 patients in twice weekly group and 46 patients in thrice weekly group. dmissing for 32 patients in thrice weekly group
  2. COVID-19, hospitalisations and deaths % calculated in relation to original number of patients n = 166 / n = 236. Abbreviations: URR Urea reduction ratio, UF Ultrafiltration